Plain-English translation of NCT02932150 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called tenofovir alafenamide () to see if it can safely and effectively treat chronic hepatitis B in children and teenagers. Researchers want to understand how well this medication works, how safe it is, and what the right doses should be for different ages and weights. About half of participants will receive the actual medication while the other half receive a placebo (a fake pill) for 24 weeks.
Chronic hepatitis B is a serious liver infection that can affect children and teenagers. While some medicines exist to treat this condition, doctors need to study whether this medication is a good option for younger patients and determine the safest and most effective doses for different age groups.
If you join this study, you will take either the new medication or a placebo once daily for 24 weeks in the form of a tablet or granules (depending on your age and weight). You'll visit the study clinic regularly so doctors can check on your health, do blood tests to monitor your liver and measure the virus level, and watch for any side effects. After the 24-week treatment period ends, you may have the option to continue receiving the active medication in an open-label phase where everyone knows they're getting the real treatment.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States